3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
2
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
pertuzumab
3
trametinib
2
palbociclib
2
dabrafenib
2
copanlisib
2
Trastuzumab
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Immunoglobulin G
2
HhAntag691
2
Fluorouracil
2
Disulfides
2
Dasatinib
2
Bevacizumab
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
venetoclax
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
temsirolimus
1
sapanisertib
1
ruxolitinib
1
romidepsin
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Inosine Monophosphate
×
Genitourinary
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled